Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, That Harbor an IDH2 Mutation

NCT02273739 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02273739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02273739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, That Harbor an IDH2 Mutation
Lead sponsor
Celgene
Phase
Phase 1/2
Overall status
Completed
Start date
December 8, 2014
Completion date
June 3, 2016
Enrollment
21 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

angioimmunoblastic t-cell lymphoma, chondrosarcoma, glioma, intrahepatic cholangiocarcinoma, solid tumor